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Highlights 
 Immunogenicity of differentiated equine mesenchymal stem cells (MSCs) was 
unknown 
 Adipogenesis and osteogenesis, but not chondrogenesis, upregulated MHC-I in 
equine MSCs 
 MHC-II expression increased after equine MSCs differentiation into the three 
lineages 
 CD40 and CD80 expression was not induced in equine MSCs after differentiation  
 MHC upregulation after differentiation might increase equine MSC immunogenicity 
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Abstract 
Mesenchymal stem cells (MSCs) are a promising treatment for equine musculoskeletal 
injuries because of their ability to regulate the inflammation and to differentiate into 
other cell types. Since interest in allogeneic therapy is rising, concerns about MSC 
immunogenicity need to be addressed. Differentiated MSCs from several species 
increase their expression of immunogenic molecules and induce alloresponses, but 
equine MSC immunogenic profile after differentiation has not been reported. Therefore, 
the aim of this study was to assess the gene expression of immunogenic markers in tri-
lineage differentiated equine bone marrow derived MSCs (eBM-MSCs). For this 
purpose, eBM-MSCs (n=4) were differentiated into osteoblasts, adipocytes and 
chondrocytes. Differentiation was confirmed by specific staining and gene expression of 
lineage-related markers. Subsequently, gene expression of MHC-I, MHC-II, CD40 and 
CD80 was analyzed in undifferentiated (control) and tri-lineage differentiated eBM-
MSCs. Osteogenesis and adipogenesis, but not chondrogenesis, significantly 
upregulated MHC-I; MHC-II expression significantly increased in the three lineages, 
while CD40 and CD80 expression did not change. Despite this, MHC-I and MHC-II 
upregulation after differentiation might lead to increased immunogenicity and risk of 
allorecognition, either eBM-MSCs differentiate in vivo after administration or they are 
differentiated prior to administration, with potential negative consequences for 
effectiveness and safety of allogeneic therapy. 
 
Keywords.- Horse; Mesenchymal stem cells; Allogeneic; Immunogenicity; 
Differentiation  
Word count.- 2,787 words 
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Introduction 
Mesenchymal stem cells (MSCs) are raising great interest for the treatment of equine 
musculoskeletal injuries since these have a huge impact in this species (Thorpe et al., 
2010), and because of the suitability of the horse as animal model (Colbath et al., 2017). 
Mesenchymal stem cells exert their therapeutic effects through different mechanisms, 
including anti-inflammatory and immunomodulatory properties, and their ability to 
differentiate into cells such as chondrocytes, osteoblasts or tenocytes (da Silva Meirelles 
et al., 2009). The regulatory properties of MSCs are currently focusing most of the 
interest, but differentiation should also be taken into account as it can occur in vivo after 
administration even if at low rates (Murphy et al., 2003; Mokbel et al., 2011). 
Furthermore, some therapeutic strategies are based on the implantation of differentiated 
MSCs, such as chondrocytes for treating joint pathologies (Broeckx et al., 2014a; Ham 
et al., 2015). The implantation of chondrocytes derived from MSCs may overcome the 
limitations of other techniques using autologous chondrocytes or chondroprogenitor 
cells, which are technically demanding and may involve donor site morbidity related to 
tissue harvesting (Jayasuriya and Chen, 2015; Cokelaere et al., 2016). Moreover, 
bioreactors are being developed to produce tissue-engineered constructs derived from 
MSCs for the repair of tissues such as cartilage, bone or tendon (Xie et al., 2013; 
Youngstrom et al., 2016).  
The optimal moment for MSC administration has yet to be determined, but several 
studies suggested enhanced effects with early administration (Koch et al., 2009; Mokbel 
et al., 2011), which might be limited by the use of autologous MSCs. Autologous 
therapy may also be limited in elderly patients or patients with genetic disorders. Hence, 
allogeneic therapy has raised great interest (Zhang et al., 2015). However, MSCs are not 
truly immune-privileged as they may induce both cellular and humoral immune 
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responses, thus their immune allorecognition would lead to negative effects both in 
terms of effectiveness, because of the elimination of the cells, and safety, because of 
potential adverse effects for the patient (Berglund et al., 2017b).  
In spite of the aforementioned, clinical implications of allogeneic equine MSCs 
administration are not entirely clear. While single and repeat intra-articular 
administration of allogeneic MSCs have been reported as clinically safe in both healthy 
(Carrade et al., 2011; Pigott et al., 2013a, b; Ardanaz et al., 2016) and pathologic equine 
joints (Broeckx et al., 2014a, b), other authors reported altered synovial parameters 
compared to autologous MSCs after second administration (Joswig et al., 2017).  
These contradictory results might be due to different levels of major histocompatibility 
complex (MHC) expression and MHC compatibility between donor and recipient, since 
positive and heterogeneous MHC-II expression level (Schnabel et al., 2014) and in vivo 
generation of antibodies against MHC-mismatched equine MSCs (Berglund and 
Schnabel, 2016) have been reported. MSC differentiation might affect their MHC 
expression and, consequently, their immunogenicity. Hence, differentiation may imply 
negative consequences for allogeneic MSC survival, potentially hampering their 
effectiveness and compromising patient safety (Lohan et al., 2014).  
Upregulation or induction of MHC-I and MHC-II and costimulatory molecules such as 
CD40 or CD80 has been shown after MSC differentiation into several lineages in 
human and small laboratory animals (Le Blanc et al., 2003; Liu et al., 2006a, b; Huang 
et al., 2010; Ryan et al., 2014; Yang et al., 2017). However, to the best of our 
knowledge, immunogenic profile of differentiated MSCs has not been assessed in the 
horse. Since allogeneic MSCs may differentiate in vivo albeit at low rates (Mokbel et 
al., 2011) or they can be differentiated to create tissue constructs prior to implantation 
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(Youngstrom et al., 2016), questions about immunogenicity of equine differentiated 
MSCs need to be addressed.  
The aim of this study was to assess the gene expression of immunogenic markers after 
tri-lineage differentiation of equine bone marrow derived MSCs (eBM-MSCs) in order 
to provide preliminary results about the potential consequences of eBM-MSC 
differentiation for their allogeneic administration. 
Material and methods 
Isolation of equine BM-MSCs 
Twenty ml of BM from sternum were collected in heparinized syringes using a 4″11G 
Jamshidi needle from four healthy horses (Shetland ponies geldings, 4-7 years, 138-162 
kg) under approval of the Ethic Committee for Animal Experiments from the University 
of Zaragoza (Project License 31/11). Gradient density separation technique 
(Lymphoprep, Atom) was used to isolate mononuclear cells, which were expanded in 
basal culture medium consisting of low glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 1%Glutamine, 1%Streptomycin/Penicillin and 10%Fetal 
Bovine Serum (FBS) (Sigma-Aldrich) until passage three and then characterized as 
eBM-MSCs by their phenotype (Ranera et al., 2011) and by their tri-lineage 
differentiation potential as it will be explained in the next section.  
Tri-lineage differentiation of equine BM-MSCs 
Equine BM-MSCs (n=4) were exposed to induction media (differentiation) or basal 
medium (undifferentiated control) in triplicates according to each differentiation assay. 
Differentiation potential was assessed by specific staining and gene expression of 
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markers for each lineage. Methodology used was previously described by Ranera et al. 
(2011). 
For inducing osteogenic differentiation, 20,000 cells/cm2 were seeded in 24-well plates. 
Osteogenic medium consisted of basal culture medium described above supplemented 
with 10nmol/l dexamethasone, 10mmol/l β-glycerophosphate and 100µmol/l ascorbate-
2-phosphate (Sigma-Aldrich). After 7 days, cells were fixed with 70%ethanol for 1 hour 
at room temperature (RT), stained with 2%Alizarin Red stain (pH 4.6) (Sigma-Aldrich) 
for 10’ RT and washed with PBS (Gibco).  
Equine BM-MSCs were seeded at 5,000 cells/cm2 in 12-well plates for the adipogenic 
differentiation with induction medium consisting of 1µmol/l dexamethasone, 500µmol/l 
3-isobutyl-1-methylxanthine, 200µmol/l indomethacin and 15% rabbit serum (Sigma-
Aldrich) supplemented basal medium. After 15 days, cells were fixed with 10%formalin 
(Sigma-Aldrich) for 15’ RT, stained with 0,3%Oil Red O stain (Sigma-Aldrich) 
(dissolved in 60:40; isopropanol:distilled water) for 30’ at 37ºC and washed with 
distilled water.  
To achieve chondrogenic differentiation, approximately 300,000 eBM-MSCs were 
transferred to conic bottom 15ml tube, 400µl of differentiation medium were added and 
then centrifuged at 1,750rpm 5’ to pellet the cells. Chondrogenic medium consisted of 
10%FBS, 10ng/ml TGFβ-3 (R&D Systems), ITS+premix (Beckton Dickinson), 
40µg/ml proline, 50µg/ml ascorbate-2-phosphate and 0.1µmol/l dexamethasone 
supplemented high glucose DMEM (Sigma-Aldrich). After 21 days, pellets were fixed 
in 10%formalin, embedded in paraffin and cut into 5µm sections. The sections were 
hydrated with increasing gradients of alcohols, stained with Mayer’s haematoxylin and 
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3%Alcian Blue dyes, rinsed with distilled water, dehydrated with decreasing amounts of 
alcohol and mounted. 
Differentiation was also assessed by analyzing the gene expression of the osteogenic 
markers Alkaline phosphatase (ALP) and Runt-related transcription factor 2 (RUNX2), 
the adipogenic markers Lipoprotein lipase (LPL) and Peroxisome proliferator-activated 
receptor γ (PPARγ), and the chondrogenic markers Collagen type II alpha I (COL2A1) 
and Aggrecan (ACAN). Methodology used for gene expression analysis will be further 
explained in the next section. 
Real time quantitative polymerase chain reaction (RT-qPCR) 
Expression of genes coding for the lineage-associated markers aforementioned and 
immunogenic markers MHC-I, MHC-II, CD40 and CD80 was analyzed by RT-qPCR. 
Isolation of mRNA and complementary DNA (cDNA) retrotranscription from all 
samples were performed with the kit Cells-to-cDNA II (Ambion) according to 
manufacturer’s instructions. 
RT-qPCR reactions were performed and monitored with a StepOne RT-PCR System 
device (Applied Biosystems), using Fast SYBR Green Master Mix (Applied 
Biosystems) and 2 µl of cDNA as template. Amplification was performed in triplicate 
as follows: 20’’ at 95°C, followed by 40 cycles consisting of 3’’/95°C and 30’’/ 60°C. 
A dissociation curve protocol was run after every reaction. Gene expression levels were 
obtained using the comparative Ct method. Normalization factor was calculated as the 
geometric mean of the quantity of two housekeeping genes, GAPDH and B2M (Ranera 
et al., 2011). Primers were designed with the Primer Express 2.0 software based on 
known equine sequences and cDNA obtained from equine peripheral blood 
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mononuclear cells (PBMCs) was used as positive control to validate the primers 
(Remacha et al., 2015). Information about primers is shown in Table 1. 
Statistical analyses 
Statistical analyses were performed using the SPSS 15.0 (SPSS Inc.). Normality of each 
data group was tested with the Shapiro-Wilk test. Differences in the expression level of 
each gene were assessed between undifferentiated (control) and differentiated cells 
within each lineage by the non-parametric paired Wilcoxon test. Significance level was 
set at P<0.05 for all analyses. 
Results and Discussion 
Equine MSCs were successfully isolated from BM from all animals and displayed 
similar phenotype (data not shown) and differentiation potential to that previously 
described (Ranera et al., 2011), as shown by specific staining (Figure 1.A) and by 
upregulated gene expression of lineage markers (p<0.05) (Figure 1.B). Control cells 
(not exposed to induction media) did not spontaneously differentiate in any case.  
Based on previous studies in other species (Le Blanc et al., 2003; Liu et al., 2006a, b; 
Huang et al., 2010; Ryan et al., 2014; Yang et al., 2017), controls with separate 
components of the differentiation media were not performed. This approach was based 
on the assumption that possible MHC upregulation would be related to phenotypic 
changes experienced by differentiated MSCs, rather than to the direct effect of media 
composition. Actually, dexamethasone may decrease MHC-II expression in 
constitutively expressing human cells (Schwiebert et al., 1995). Indomethacin is a non-
steroidal anti-inflammatory agent which inhibits prostaglandin(PG)-E2 production. 
Since PGE2 may participate in MHC regulation, their inhibitors might influence MHC 
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expression (Otsuka et al., 1991; Kim et al., 2010). However, to the best of our 
knowledge it has not been reported modification of MHC expression in MSCs by 
indomethacin. Members of the TGFβ family are usually found in immune-privileged 
tissues (Siglienti et al., 2007) and TGFβ-2 diminished MHC expression in equine MSCs 
(Berglund et al., 2017a), so it would not be expected that the isoform TGF-β3 had 
upregulated MHC. Finally, as far as we are concerned, the other components used in the 
differentiation media have not been described to affect MHC expression.  
The results presented in this study are refered to gene expression, which has been 
widely used to study differentiated MSCs as it reflects their response to their 
environment in terms of control of protein production. However, mRNA traduction into 
proteins is a complex process so gene expression may not exactly correlate with protein 
expression. Nevertheless, increased MHC expression has been observed in both terms 
of gene and surface (protein) expression in undifferentiated equine MSCs exposed to 
inflammatory stimuli (Barrachina et al., 2016). Moreover, previous studies in other 
species assessing MHC expression in differentiated MSCs reported its increase in terms 
of both gene and protein expression (Huang et al., 2010; Xia and Cao, 2013). Therefore, 
gene expression changes found in this study may be related to surface protein changes, 
albeit at different extent. Further analyses, including protein expression and cytotoxicity 
assays, are warranted; but current gene expression results provide a preliminary insight 
about changes in the immunogenicity of differentiated equine MSCs.  
Gene expression of MHC-I was significantly upregulated, compared to the 
undifferentiated control, in both osteogenic (p<0.01) and adipogenic (p<0.01) 
differentiated eBM-MSCs, but not in the cells undergoing chondrogenesis (Figure 2.A). 
On the contrary, MHC-I expression did not increase in human MSCs differentiated into 
osteogenic and adipogenic lineages but was upregulated after chondrogenesis (Le Blanc 
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et al., 2003). Interestengly, in the study of Le Blanc, MHC-I expression after 
adipogenesis was slightly reduced, while in our study this lineage showed the greatest 
MHC-I upregulation.  
MHC-II gene expression significantly increased in eBM-MSCs differentiated into the 
three lineages (p< 0.05 for osteogenesis and adipogenesis, p<0.01 for chondrogenesis) 
(Figure 2.B). However, differentiated human MSCs did not show increased MHC-II 
expression in any lineage (Le Blanc et al., 2003), as well as no MHC-II expression was 
found in insulin-producing cells derived from human MSCs (Yang et al., 2017). On the 
contrary, human MSCs undergoing neuronal differentiation (Liu et al., 2006a) and 
murine MSCs differentiated into osteoblast (Zhang et al., 2009) and myocardiocytes 
(Huang et al., 2010) did upregulate MHC-II expression. 
On the other hand, neither CD40 nor CD80 gene expression significantly changed in 
differentiated eBM-MSCs compared to undifferentiated cells (Figure 2.C and 2.D). In 
basal conditions, MSCs do not express costimulatory molecules such as CD40, CD80 or 
CD86 (Wang et al., 2014) but inflammatory exposure may lead to CD40 upregulation 
(Najar et al., 2012; Barrachina et al., 2017). Similarly to our results, insulin-producing 
cells derived from human MSCs showed no expression of CD40 or CD80 (Yang et al., 
2017). Osteogenic differentiation neither induced CD80 nor CD86 expression in murine 
MSCs (Zhang et al., 2009), but osteogenesis (Shi et al., 2010) and neurogenesis (Liu et 
al., 2006a) of human MSCs led to CD80 expression.  
Thus, a great variability has been observed in the immunogenic profile of differentiated 
MSCs among species and lineages. Therefore, it is needed to assess these changes in 
each case to clarify the potential implication of MSC differentiation in their 
immunogenicity and, consequently, in their effective and safe administration. To the 
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best of our knowledge, this is the first study reporting the influence of the osteogenic, 
adipogenic and chondrogenic differentiation of equine MSCs on their immunogenic 
gene expression profile. 
Hence, upregulation of MHC-I and MHC-II might be related to an increased risk of 
immune allorecognition of the differentiated eBM-MSCs. Allorecognition of MHC 
molecules can be triggered by both direct and indirect pathways, that is, through the 
direct recognition of MHC-I and MHC-II molecules expresed by donor MSCs by 
recipient CD8+ or CD4+ T-cells (Chan et al., 2006; Afzali et al., 2008), or through the 
internalization of allogeneic MHC-I and MHC-II fragments by the recipient antigen 
presenting cells and their subsequent presentation to B and T-cells, potentially leading 
to cellular and humoral responses involving the generation of immune memory, which 
may limit repeat administration (Consentius et al., 2015). Furthermore, natural killer 
(NK)-cells could also target allogeneic MSCs that are missing self-MHC since they 
would be unable to activate the NK-cell inhibitory receptors (Spaggiari et al., 2006). 
Equine MSCs expressing MHC-II directly induced proliferation of allogeneic MHC-
mismatched T-cells in vitro (Schnabel et al., 2014), so MHC upregulation after 
differentiation might play a similar role. Activation of naïve T-cells requires 
costimulatory signals provided by costimulatory molecules such as CD40 and CD80 
(Tse et al., 2003), which were not upregulated after differentiation of eBM-MSCs in this 
study. Even though the lack of costimulatory molecules expression in MSCs has been 
proposed to partially explain the absence of alloresponse in some situations (Consentius 
et al., 2015), the solely recognition of allogeneic MHC molecules may activate memory 
and effector T-cells, leading to an immune rejection (Benichou et al., 2017). 
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Consequently, MHC upregulated gene expression might be hypothesized to potentially 
increase the risk of immune allorecognition of eBM-MSCs after differentiation, even 
though costimulatory molecules were not upregulated. However, previous studies in 
other species did not always correlate the changes in the immunogenic profile of 
differentiated MSCs with an increased immune response in vitro (Le Blanc et al., 2003; 
Liu et al., 2006a; Zhang et al., 2009).On the contrary, other studies observed that 
differentiated MSCs induced proliferation of allogeneic T-cells in vitro (Shi et al., 2010; 
Ryan et al., 2014) and local and systemic T-cell memory response in vivo (Ryan et al., 
2014). Moreover, while allogeneic administration of undifferentiated MSCs did not 
show adverse effects and even therapeutic benefit was elicited, administration of 
allogeneic pre-differentiated cells (Xia and Cao, 2013) or MSC differentiation in vivo 
after injection (Huang et al., 2010; Gu et al., 2015) led to immune rejection associated 
to MHC-I and MHC-II induction. Thus, previous studies suggest that allogeneic MSCs 
would go from a regulatory status (undifferentiated) towards an immunogenic one after 
differentiation, only providing short-term therapeutic benefit since differentiated cells 
would be rejected. This immunogenicity increase might be not only due to increased 
MHC expression but also related to a loss of MSC immunomodulatory ability (Ryan et 
al., 2014). In addition, different results observed in vitro and in vivo might be also 
explained by the potential influence of the in vivo microenvironment. As 
proinflammatory cytokines may upregulate MHC expression in undifferentiated MSCs 
(Barrachina et al., 2016), inflammatory conditions might also play a role in the 
immunogenicity of differentiated MSCs in vivo (Yang et al., 2017). 
Summarizing, current knowledge about how differentiation influences MSC 
immunogenicity presents some contradictions but evidences that MSC immune 
properties could be affected, warranting further research in this area. The present study 
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provides preliminary data about the changes induced by differentiation in the 
immunogenic profile of eBM-MSCs. Gene expression of MHC-I and MHC-II, but not 
CD40 and CD80, was increased after tri-lineage differentiation of eBM-MSCs, which 
might influence their immunogenicity and, subsequently, their allogeneic use, either if 
differentiation may occur in vivo after administration or whether equine MSCs are 
previously differentiated for a tissue engineering approach. Implications of these 
findings for the allorecognition of differentiated eBM-MSCs needs to be further 
addressed, as well as the possible role of the in vivo microenvironment and the effect of 
differentiation on immunomodulatory ability of eBM-MSCs, since MSC immune 
properties play a key role in the development of effective and safe cell therapies. 
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Table 1.- Primers used for gene expression by RT-qPCR. GenBank accession numbers 
of the sequences used for primers design. Primers (F: Forward and R: Reverse) and 
length of the amplicon in base pair (bp). Genes were grouped in agreement with the 
functions and implications of encoded molecules.  
GENE 
Accession 
number 
Primer sequence (5‘–3’) 
Amplicon 
size 
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HOUSE-KEEPING 
GAPDH NM_001163856 
F:GGCAAGTTCCATGGCACAGT 
R:CACAACATATTCAGCACCAGCAT 
128 
B2M NM_001082502.2 
F: TCGTCCTGCTCGGGCTACT 
R: ATTCTCTGCTGGGTGACGTGA 
102 
IMMUNOGENICITY-RELATED MOLECULES 
MHC-I AB525081 
F: CGTGAGCATCATTGTTGGC 
R: TCCCTCTTTTTTCACCTGAGG 
92 
MHC-II NM_001142816 
F: AGCGGCGAGTTGAACCTACAGT 
R: CGGATCAGACCTGTGGAGATGA 
172 
CD40 AY514017 
F: ACAAATACTGCGACCCCAACC 
R: TTTCACAGGCATCGCTGGA 
114 
CD80 Krampera 2006 
F: CAGGAAAGTTGGCTCTGACCA 
R: TCTCCATTGTGATCCTGGCTC 
135 
OSTEOGENIC MARKERS 
ALP XM_001504312 
F: GATGGCCTGAACCTCATCGA 
R: AGTTCGGTCCGGTTCCAGAT 
92 
RUNX2 XM_001502519.3 
F: CTCCAACCCACGAATGCACTA 
R: CGGACATACCGAGGGACATG 
80 
ADIPOGENIC MARKERS 
LPL XM_001489577 
F:TGTATGAGAGTTGGGTGCCAAA 
R:GCCAGTCCACCACAATGACAT 
70 
PPARγ XM_001492411 
F:TGCAAGGGTTTCTTCCGGA 
R:GCAAGGCATTTCTGAAACCG 
104 
CHONDROGENIC MARKERS 
ACAN AF019756 
F: CTACGACGCCATCTGCTACA 
R: ACCGTCTGGATGGTGATGTC 
96 
COL2A1 XM_005611082.1 
F: TTAGACGCCATGAAGGTTTTCTG 
R: CTCTTGCTGCTCCACCAGTTCT 
101 
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Figure legends 
Figure 1.- Tri-lineage differentiation induction was confirmed by specific staining (A) 
and gene expression (B). Alizarin red staining of eBM-MSCs differentiated into 
osteoblasts (magnification 20x) (A.1); Oil red O staining of eBM-MSCs differentiated 
into adipocytes (magnification 4X) (A.2) and Alcian Blue staining of pellets from eBM-
MSCs undergoing chondrogenic differentiation (maginification 10X) (A.3). Results 
from gene expression are expressed as Mean ± S.E.M (n=4) fold change of 
differentiated eBM-MSCs over undifferentiated eBM-MSCs (control) for osteogenic 
(B.1), adipogenic (B.2) and chondrogenic (B.3) markers. ALP, Alkaline phosphatase; 
RUNX2, Runt-related transcription factor 2; LPL, Lipoprotein lipase; PPARγ, 
Peroxisome proliferator-activated receptor γ; COL2A1, Collagen type II alpha I; 
ACAN, Aggrecan; * = p<0.05. 
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Figure 2.- Gene expression data are reported as Mean ± S.E.M (n=4) fold change of 
osteogenic, adipogenic and chondrogenic differentiated eBM-MSCs over 
undifferentiated eBM-MSC (control) for the immunogenic markers MHC-I (A), MHC-
II (B), CD40 (C) and CD80 (D). MHC-I, major histocompatibility complex type I; 
MHC-II, major histocompatibility complex tipe II; CD40, cluster of differentiation 40; 
CD80, cluster of differentiation 80; * = p<0.05; ** = p<0.01 
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